BACKGROUND: The purpose of this study was to examine the 15-year survivorship and long-term clinical outcomes of the GENESIS II total knee arthroplasty (TKA). METHODS: Patients who underwent TKA with the GENESIS II system between 1995 and 1999 were retrieved from our institutional database. We report a Kaplan-Meier survival analysis as well as Western Ontario and McMaster Universities Arthritis Index, the Short Form Health Survey-12 (SF-12), and the Knee Society Scores at a mean of 16 years. RESULTS: Four-hundred sixty-nine TKAs were performed with a mean patient age of 68 years. Patients were followed up prospectively for a mean of 16 years (range, 14.8-19.5 years). The Kaplan-Meier survival analysis at 15 years, with revision for any reason as the end point, was 96.4% (95.5%-97.3%). The Western Ontario and McMaster Universities Arthritis Index and the Knee Society Scores were significantly improved (P < .001) from the preoperative period to the latest follow-up. Patients had a significant improvement (P < .001) from the preoperative to the latest follow-up on the Physical Health Composite Score of the SF-12, but no change was noted on the Mental Health Composite Score of the SF-12. CONCLUSION: The unique design features of the GENESIS II TKA system have remained a constant over the duration of its clinical use, a rarity for contemporary TKA systems which are often altered before the publication of long-term results. The GENESIS II continues to demonstrate excellent long-term survivorship and improvements in health-related outcomes at a mean of 15 years, representing the standard for TKA systems at our institution.
BACKGROUND: The purpose of this study was to examine the 15-year survivorship and long-term clinical outcomes of the GENESIS II total knee arthroplasty (TKA). METHODS:Patients who underwent TKA with the GENESIS II system between 1995 and 1999 were retrieved from our institutional database. We report a Kaplan-Meier survival analysis as well as Western Ontario and McMaster Universities Arthritis Index, the Short Form Health Survey-12 (SF-12), and the Knee Society Scores at a mean of 16 years. RESULTS: Four-hundred sixty-nine TKAs were performed with a mean patient age of 68 years. Patients were followed up prospectively for a mean of 16 years (range, 14.8-19.5 years). The Kaplan-Meier survival analysis at 15 years, with revision for any reason as the end point, was 96.4% (95.5%-97.3%). The Western Ontario and McMaster Universities Arthritis Index and the Knee Society Scores were significantly improved (P < .001) from the preoperative period to the latest follow-up. Patients had a significant improvement (P < .001) from the preoperative to the latest follow-up on the Physical Health Composite Score of the SF-12, but no change was noted on the Mental Health Composite Score of the SF-12. CONCLUSION: The unique design features of the GENESIS II TKA system have remained a constant over the duration of its clinical use, a rarity for contemporary TKA systems which are often altered before the publication of long-term results. The GENESIS II continues to demonstrate excellent long-term survivorship and improvements in health-related outcomes at a mean of 15 years, representing the standard for TKA systems at our institution.
Authors: Philip P Roessler; Randa Moussa; Cornelius Jacobs; Karl F Schüttler; Thomas Stein; Frank A Schildberg; Dieter C Wirtz Journal: Int Orthop Date: 2018-08-01 Impact factor: 3.075
Authors: Matthew G Teeter; Jacob Wihlidal; Richard W McCalden; Xunhua Yuan; Steven J MacDonald; Brent A Lanting; Douglas D Naudie Journal: Clin Orthop Relat Res Date: 2019-01 Impact factor: 4.176
Authors: Lucas Beckers; Jacobus H Müller; Jeremy Daxhelet; Salvatore Ratano; Mo Saffarini; Tarik Aït-Si-Selmi; Michel P Bonnin Journal: Knee Surg Sports Traumatol Arthrosc Date: 2021-06-01 Impact factor: 4.342
Authors: Jonathan T Evans; Robert W Walker; Jonathan P Evans; Ashley W Blom; Adrian Sayers; Michael R Whitehouse Journal: Lancet Date: 2019-02-14 Impact factor: 79.321
Authors: Jaap J Tolk; Rob P A Janssen; Tsjitske M Haanstra; Sita M A Bierma-Zeinstra; Max Reijman Journal: Trials Date: 2018-08-14 Impact factor: 2.279